Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin
Rick A. Bright(Waterford Institute), Ted M. Ross(Cleveland Clinic), V. I. Gavrilov(Novavax (United States)), Thomas Rowe(University of Georgia), Donald M. Carter(Vaccine & Gene Therapy Institute of Florida), Attiya Ahmad(Novavax (United States)), Shannon Daniluk(Novavax (United States)), Peter Pushko(Novavax (United States)), Franklin R. Toapanta(University of Maryland, Baltimore), Gale Smith(Novavax (United States)), Nutan Mytle(Southern Research Institute), Mike Massare(Novavax (United States))
Cited by 290
Related Papers
Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern
|The Lancet|2005|734
Adamantane Resistance Among Influenza A Viruses Isolated Early During the 2005-2006 Influenza Season in the United States
|JAMA|2006|672
Transmission of Equine Influenza Virus to Dogs
|Science|2005|652
Changes in Influenza and Other Respiratory Virus Activity During the COVID-19 Pandemic — United States, 2020–2021
|MMWR Morbidity and Mortality Weekly Report|2021|611
Surveillance of Resistance to Adamantanes among Influenza A(H3N2) and A(H1N1) Viruses Isolated Worldwide
|The Journal of Infectious Diseases|2007|547